Personalis to Participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference

Personalis to Participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference




Personalis to Participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference

MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the 6th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference on Tuesday, August 17, 2021.

About Personalis, Inc.

Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA MVP. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing Personalis’ biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis’ Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

Contacts

Investor Relations Contact:

Caroline Corner

investors@personalis.com
www.westwickepartners.com
415-202-5678

Media Contact:

Jennifer Havlek

pr@personalis.com
www.personalis.com
650-752-1300